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List of Tables ii Sfry "Rebound insomnia," a worsening of sleep compared to pretreatment levels, has been reported upon discontinuation of short half-life benzodiazepine hypnotics. This paper reviews the existing sleep laboratory studies for the presence or absence of rebound insomnia following treatment with triazolam, temazepam, and flurazepam in insomniac patients or "poor sleepers," and, when possible, in normals.
The results indicate that rebound insomnia is a distinct possibility after discontinuation of triazolam in both insomniacs and normal controls.
Compared with baseline, disturbed sleep was reported in insomniacs or poor sleepers for the first one or two nights of withdrawal in seven of nine polygraphically recorded sleep studies following triazolam (0.5 and in one of two studies with an adequate number of subjects f6ilowing triazolam (0. 25 . In one study conducted in normal volunteers, rebound insomnia was observed following triazolam (0.5 g) but not triazolam (-_. 25 . In one study, which used subjective reports of sleep rather than polygraphic > irecordings, rebound insomnia was significantly attenuated after triazolam (0.5 ag) by tapering the dose over four nights. The risk of rebound insomnia after temazepam (15 or 30 ) was low. In keeping with its long elimination half-life, flurazepae (30 continued to exert beneficial effects for the first two to three withdrawal nights, but the possibility of a mild rebound insomnia cannot be dismissed during the intermediate withdrawal period (nights 4-10) following prolonged, consecutive, nightly administration (more than
The benzodiazepine hypnotics are generally preferred over other types (barbiturates or non-benzodiazepines, non-barbiturates), but there are advantages and disadvantages related to half-life of the benzodiazepines. The risk of rebound insomnia is greater with the short half-life as compared with the long half-life benzodiazepines.
INTRODUCTION
Rebound or withdrawal symptoms are potential problems when discontinuing sedative and anxiolytic drugs.
Physical dependence is well documented with high dose, long-term administration of both barbiturates and benzodiazepines in humans (1, 2) . Fortunately, the frequency of major withdrawal events appears to be low in clinical practice when considering the large number of people receiving prescriptions for these medications (3, 4) .
More recently, it has been shown that discontinuation of anxiolytics and sedative-hypnotics may produce withdrawal symptoms even if these drugs had been administered at recommended doses (5) (6) (7) (8) (9) (10) (11) (12) .
Different types of symptoms have been described: (a) symptom reemergence, the reappearance of the original symptoms for which the patient originally sought treatment, (b) symptom intensification, an exacerbation of the original symptoms, and (c) symptom creation, the appearance of new symptoms during withdrawal which were not present before treatment (10). For example, symptom reemergence and intensification, and the appearance of new symptoms were shown in a recent, double-blind, placebo-controlled study of patients who had received benzodiazepine doses equivalent to approximately 14-16 mg diazepam for 72-75 months (12) . Symptoms occurred earlier following short half-life benzodiazepines compared with long half-life benzodiazepines. Moreover, withdrawal symptoms have also been precipitated in baboons, who had been treated with diazepam for a week, by the administration of RO 15-1788, a specific Leceptor antagonist of benzodiazepines (13) .
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In the case of sleeping medicines, Kales and his group have identified two syndromes of disturbed sleep. First, they (14) described a condition which they called "drug-withdrawal insomnia," which occurs following abrupt discontinuation of nonbenzodiazepine hypnotics (i.e., barbiturates, chloral hydrate, etc.,) administered in multiple doses over long periods of time.
This syndrome is characterized by increased sleep latency, disrupted and fragmented sleep, and increased dreaming associated with a REM sleep rebound during the withdrawal period. They attributed drug-withdrawal insomnia to the psychological and physiological changes involved in drug discontinuation and considered it part of a general abstinence syndrome resulting from withdrawal of central nervous system (CNS) depressant drugs administered at high doses or for long periods of time.
Kales et al (15-18) later described "rebound insomnia" as a potential problem upon stopping short, half-life benzodiazepine hypnotics which had been taken at recommended doses for even short periods of time. For example, sleep latency and total wake time increased during the early rebound period compared with pretreatment, baseline levels.
They interpreted rebound insomnia as a classical withdrawal phenomena, perhaps reflecting up-regulated benzodiazepine recognition sites resulting from receptor blockade.
In the context of prescribing patterns in the United States, Kales and his colleagues singled out triazolam as the primary offending agent in rebound insomnia.
Of the three marketed benzodiazepine hypnotics -- Rebound insomnia has been a controversial concept (20) (21) . In part, the controversy centered around the definition of rebound insomnia. Kales et al (15) originally emphasized increased sleep latency, wake time after sleep onset, and total wake time, but Hartse et al (20) objected that these three measures were not all abnormal in every study. In addition, Nicholson (21) 4 expressed concern about maintaining the "blind" in studies which concluded with a placebo period, especially where the patient was more likely to recognize placebo substitution following a short half-life compared with a long half-life hypnotic. Finally, Nicholson (21) concluded from his review of available literature at that time, that there was "little or no experimental evidence that proper use of a short-acting hypnotic, triazolam, leads to worsening of sleep on withdrawal, and this is supported by studies with another short-acting drug, temazepam."
Moreover, some investigators have suggested that rebound insomnia is not unique to short half-life benzodiazepine hypnotics. It may occur, for example, with long half-life hypnotics such as flurazepam, but at a later time during withdrawal.
Two other problems, possibly related to partial withdrawal from short half-life hypnotics, were also described during the course of nightly administration of triazolam for more than a week or so: increased daytime anxiety (22) and early morning insomnia (23).
In this paper, we review the existing literature on rebound insomnia and early morning insomnia for flurazepam, triazolam, and temazepam, concentrating on sleep-laboratory studies of patients with insomnia or who are described as "poor sleepers."
Because sleep often improves spontaneously over time in longitudinal studies of insomnia, a particularly useful research design employs a parallel, independent, placebo-treated group.
This design provides both within-group and between-group comparisons for treatment and withdrawal effects. Unfortunately, only a few studies used this design. Therefore, we have usually compared sleep measures during the withdrawal and baseline periods to determine rebound effects.
In addition, since tolerance may be related to physical dependence and withdrawal symptoms, we examined sleep during the treatment period.
The specific sleep indices of drug efficacy and rebound insomnia varied from study to study and included total sleep time, sleep efficiency (percent of time in bed spent asleep), sleep latency (time to fall asleep), wake time after sleep onset (WASO), total wake time, and early morning awakening. No single sleep measure was present in all available studies. We concentrated upon total sleep time when this measure was available or could be calculated from other data provided in the specific study, and refer to other measures such as sleep latency, sleep efficiency, and wake time after sleep onset when these were available.
When data from individual nights during treatment or withdrawal were available, we examined them.
Otherwise, we used data from grouped nights (i.e., the average of three recovery nights) when these were available. In order to facilitate comparisons within groups and between groups in this paper, we frequently present specific sleep indices for treatment and withdrawal periods as a percentage of baseline values.
RESULTS

Triazolam
Sleep findings were reviewed in 11 all-night sleep laboratory studies in which triazolam was administered to chronic insomniacs or "poor sleepers" in a placebo-triazolam-placebo design (24-34) ( Table 1) .
Only two of the 11 studies in this review of triazolam used an independent, parallel placebo-treated group (30, 33) . Duration of treatment ranged from 4-37 consecutive nights.
The dose was 0.5 mg in nine studies, 0.25 mg in three studies (3 patients in one study (24) , 6 patients each, in two studies (28,34)] and 1.0 mg in one study of 3 patients (24).
In five studies, all of which used a dose of 0.5 mg, data from individual nights were available during either hypnotic treatment or withdrawal (24, 25, (31) (32) (33) . In other studies, data were averaged or grouped for specific time periods before, during, and after treatment with triazolam.
Rebound Insomnia
Results from seven of the nine studies on triazolam (0.5 mg) suggested Table 1 ).
In one of these studies, the rebound changes reported were small [see Roth et al (25) ].
In two other studies, no Pegram et al (29) , and Spinweber and Johnson (30) .
In the studies reporting rebound insomnia, the specific indices showing deteriorated sleep during withdrawal varied from study to study. Therefore, we present the results for each measure separately ( Table 1) .
In two studies of triazolam (0.25 mg) each of which employed 6 patients, evidence of rebound insomnia was not found in one study [Roth et al (28) ], but was reported in the second in which a significant increase of total wake 
to about 41-42/ below baseline values (31, 32) . The changes on the first withdrawal night in the study by Hitler et al (33) were in-between, but were statistically significant by both within-group and between-group comparisons.
The average reduction of total sleep time in these six studies was 24.5% from baseline or about 85 minutes less sleep on the first night of withdrawal than during pretreatment baseline.
On the second and subsequent withdrawal nights, total sleep tended to return to baseline levels or even exceeded it, but considerable variability between studies was noted.
In one of the three studies reporting grouped or mean data for withdrawal nights, Kales et al (27) reported that total sleep time was Data on wake time after sleep onset were reported in three studies, all of which reported rebound insomnia. In two of these, it was increased during the first withdrawal nights [Kales et al (27) and Adam et al (31)] but not in the study by Mitler et al (33) .
In their study of triazolam (0.5 mg), Roth et al (25) found that stage wake, as a percentage of the night, increased a small but significant amount during the four-night withdrawal period compared with baseline (from 11.3%-12.8%, p<.05) but total wake time in minutes was unchanged. They did not report either total sleep time or sleep efficiency; no other measures of rebound insomnia were significant in their study.
In more recent papers, Kales et al (17, 18) defined rebound insomnia as a "statistically significant increase or an increase of 40% or greater in the mean group value for total wake time for a single withdrawal night or the entire withdrawal condition as compared with baseline." In the four studies of triazolam (0.5 mg) reviewed in Table 2 , total wake time increased during withdrawal on the first withdrawal night or throughout the three-night withdrawal period in three studies [Vogel et al (24, 26) and Kales et al (27) ].
On the other hand, Spinweber and Johnson (30) found a nonsignificant reduction in total wake time during withdrawal from triazolam (0.5 mg). In an attempt to assess individual differences in rebound insomnia, Bixler et al (36) compared a group treated with triazolam (0.5 mg) for two weeks with a composite group consisting of placebo-treated patients.
The rate of rebound insomnia was calculated by determining the number of r withdrawal nights in which total wake time exceeded the baseline mean total wake time by two standard errors of the mean. By this definition, the rate of rebound insomnia was significantly higher in the triazolam group than in the placebo group (61.9% versus 13.3%, p<.01). 
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these patients showed no significant changes in sleep during either the first or last three nights of the two-week treatment period (Table 2) .
Vogel et al (24) found no rebound insomnia in their more limited study of 3 patients who received triazolam 0.25 mg for 7 nights. Vogel et al (24) showed about a 5% increase in total sleep time during treatment and about a 3% reduction during withdrawal.
In the same study, the 6 patients who 
Flurazepam
Ten all-night sleep laboratory studies were reviewed in which flurazepam was administered to chronic insomniacs or "poor sleepers" in a placeboflurazepam-placebo design (Table 3) (26,33,37-44) .
The dose was 30 mg per night in nine studies, and 15 mg in one (Roehrs et al (43)]. Flurazepam was given for periods ranging from 4-37 consecutive nights.
In three studies, data from individual nights were available for either total sleep time or sleep efficiency during hypnotic treatment or withdrawal (26, 33, 44) .
In other studies, data were averaged or grouped for specific times before, during, and after treatment with flurazepam.
Sleep was recorded on the first 2 or 3 nights of withdrawal in all studies.
Because of the long half-life issues with flurazepam, several studies also recorded additional, later nights during withdrawal: the first 
Rebound Insomnia
None of the ten studies showed evidence of rebound insomnia during the early withdrawal period following flurazepam (15 or 30 mg) .
Nevertheless, there were inconclusive suggestions of a delayed, generally-mild rebound insomnia.
Flurazepam (30 mg):
The results for total sleep time are shown in Figures 3 and 4 , and Table 3 .
During the final period of flurazepam treatment, total sleep time was increased in four (26, 40, 42, 44) of the five Data on the first three withdrawal nights were presented in all studies.
In addition, data were also presented on withdrawal nights 12-14 [Bixler et al (45) (46) reported that it significantly increased total sleep time through the 
Temazepam (15 mg):
The short-term clinical effectiveness of temazepam (15 mg for two weeks) was shown in two studies (46, 48) . In the first, Hitler et al (46) showed that total sleep time improved significantly by analysis of variance and was about 11% above baseline levels at the end of the 1A nights 23 of treatment.
In the second study, Kales et al (48) found that temazepam significantly decreased wake time after sleep onset, total wake time, and increased sleep efficiency, with apparent partial tolerance for sleep efficiency and total wake time on drug nights 12-14.
During acute withdrawal, neither study reported significant sleep changes consistent with rebound insomnia. However, Kales et al (48) found increases of 11% and 13% in total wake time on the first and fourth recovery nights, respectively (p NS).
Wakefulness was significantly increased during the first and second thirds of the first recovery night.
In the only study contrasting temazepam (15 mg) with another hypnotic, Kales et al (48) reported that sleep latency was significantly shorter during the first 3 withdrawal nights in the quazepam group than in the temazepam group.
Early Morning Insomnia
Early morning insomnia has not been reported with temazepam in the studies reviewed. We will return to this problem later and suggest a possible answer.
Rebound insomnia after triazolam (0.25 mag) was reported in one study (34) but not in another (28) . The patients in the study reporting rebound insomnia were older and were treated for a longer period of time than those in the other study which did not find rebound insomnia.
In a recent study, in healthy normal sleepers (21-35 years old), Roehrs et al (49) administered placebo or triazolam (either 0.25 or 0.5 mg) for 6 consecutive nights.
Although both doses reduced total wake time significantly during treatment, significant rebound insomnia (increased total wake time, increased sleep latency and increased latency back to sleep after awakening 2.5 hours from bedtime) occurred following the 0.5 mg dose, not the 0.25 mg dose.
These studies show that rebound insomnia may occur in both insomniacs and normal controls. In the case of triazolam (0.25 mg), the risk of rebound insomnia may be greater in middle-aged or older patients who have been treated for at least two weeks compared with young insomniac patients or normal controls treated for a week. Since hypnotics are often recommended in the management of transient insomnia occurring in otherwise healthy, normal sleepers, the apparently low risk of rebound insomnia following triazolam (0.25 mg for up to 7 nights) may be clinically important.
Further studies will be reviewed to assess the role of age and duration of treatment.
Rebound insomnia does not appear to be related to either the magnitude of improved total sleep time or to tolerance during treatment. Further, the occurrence of rebound insomnia following treatment with triazolam does not appear to be related to whether or not triazolam improved sleep during treatment. Rebound insomnia occurred in a study in which triazolam (0.25 mg) did not improve sleep in insomniac patients (34). It also failed to occur in a study in which triazolam (0.25 mg) did promote sleep in normals (49) and in a study in which triazolam (0.5 mg) did not help insomniac patients (29) .
When triazolam (0.5 mg) is administered, it may be possible to attenuate rebound insomnia by tapering the dose gradually.
Greenblatt et al (50) compared 30 patients with insomnia who underwent abrupt discontinuation following triazolam (0.5 mg for 7 to 10 nights) and 30 patients who were gradually withdrawn (0.25 mg for 2 nights, 0.125 mg for 2 nights, and then placebo) following triazolam (0.5 mg for 7 nights). The former group showed rebound insomnia according to subjective criteria (increased sleep latency, awakenings, and decreased sleep duration); the latter group showed only modest rebound insomnia compared with pretreatment levels.
None of the studies reviewed found major rebound insomnia following withdrawal from either 15 mg or 30 mg doses of temazepam, even after 33 consecutive nights of treatment (30 mg).
Nevertheless, in a 33-night study, Mitler et al (46) reported a 41.5% increase in wake time after sleep onset (p NS) for the 3 withdrawal nights following temazepam (30 mg). In addition, Kales et al (48) found significantly increased wakefulness during the first and second third of the first withdrawal night following temazepam 15 mg. Therefore, though the risk may be low, it appears prudent to consider the possibility of rebound insomnia following temazepam and to await the results of future clinical experience and research before concluding that it never happens.
In the case of flurazepam (30 rg), hypnotic benefits continue for I to 3 nights of withdrawal.
Beyond the first 2 or 3 nights of withdrawal, the likelihood of rebound insomnia appears to be low.
Perhaps the strongest suggestion comes from the study of hitler et al (33) (see Johnson et al (35)], who reported that total sleep time was significantly lower and that sleep efficiency tended to be lower during the second week of withdrawal compared with both baseline and the parallel, placebo group.
It may be important that this was the only study in which: (a) flurazepam (30 mg) was administered for more than four weeks, and (b) comprehensive measures of sleep were published on withdrawal nights 8-9.
In addition, Kales et al (41), found increased total wake time (from about 100 minutes per night to about 120 minutes) on nights 4 and 14.
These observations suggest that rebound insomnia may occur in some patients at some time during the fourth through fourteenth night of withdrawal.
Further research is needed to evaluate the probability and clinical significance of rebound insomnia, if any, or otherwise disturbed sleep during the intermediate withdrawal period
following flurazepam 30 mg.
In discussing the paper of Mitler et al (33), Kales (51) has argued that the study suffers because time in bed was not controlled and this might account for the findings in the study. A counter argument is that the "real world" situation, where subjects choose how long they wish to stay in bed, is a more realistic method of assessing hypnotic effects.
Also, the use of sleep efficiency rather than total sleep time in the analysis took into account the varying time-in-bed for each patient [Johnson et al (35) ]. These arguments are not easily resolved.
Data were not available beyond the first three nights of withdrawal following administration of flurazepam 15 mg dose. Based upon these limited data, no rebound insomnia was observed.
In future definitions of rebound insomnia, it seems appropriate to accept significant deterioration in one or more sleep measures such as: increased sleep latency, increased total wake time or wake time after sleep onset, reduced total sleep time, or reduced sleep efficiency.
Studies of hypnotic agents, however, ought to report all these variables and their definitions for each.
Since time in bed may be an important factor, it should also be included in the data presentation and the investigators should state whether they or the subjects determined it.
In addition, full data from individual nights should be statistically analyzed and presented, when appropriate. A sufficient number of withdrawal nights should be included to determine whether delayed rebound insomnia exists.
Furthermore, in addition to analysis of mean differences, a more sensitive approach would be to compare each subject's worst withdrawal sleep nights against his/her worst pretreatment sleep. Within subject comparison of worst pretreatment and withdrawal sleep would help overcome the bias toward rebound insomnia when an average of baseline values are used or when the night prior to actual treatment is used. Bias toward reporting rebound insomnia, especially when within group studies are done, can occur because sleep usually improves during baseline, especially if a placebo is given. In this instance, is the insomnia a symptom reemergence or symptom intensification?
In addition, we recommend that future investigations calculate the rate of rebound insomnia amongst subjects, i. Early morning insomnia was not the focus of the sleep laboratory studies reviewed here. In the limited data available, early morning insomnia was not reported in most of the studies.
However, in view of the published data suggesting this problem, further research is needed to establish the frequency and severity of this and other side effects of short half-life hypnotics.
None of these studies reviewed or investigated the effects of intermittent or occasional use. Results from the current studies where these drugs were administered on a consecutive, nightly basis may not be generalized to this more common intermittent pattern of use.
In choosing the appropriate dose of a benzodiazepine hypnotic, the clinician faces a narrow therapeutic range.
For most patients, the upper recommended doses are likely to produce various side effects [for example, rebound insomnia for triazolam (0.5 mg) and daytime hangover effects for flurazepam (30 mg)]. For some patients, the lower doses of triazolam (0.25 mg or 0.125 mg), flurazepam (15 mg), or temazepam (15 mg), may be effective but tolerance may develop more quickly to the lower dose than to the higher dose.
Though the data are limited, studies have indicated that rebound insomnia and other side effects are less likely at lower doses. 
